Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma

NCT00667342 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.

NCT NCT00667342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00667342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma
Lead sponsor
St. Jude Children's Research Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 3, 2008
Completion date
August 31, 2017
Enrollment
43 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

malignant fibrous histiocytoma (mfh) of bone, osteosarcoma